A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

SHR-A1811 is being tested in a biomarker-selected, late-line recurrent/metastatic cervical cancer population, so there is a plausible mechanism-driven path to activity. The setup is favorable for a Phase II readout: this is a single-arm study with objective response rate as the primary endpoint, and responses are assessed by an independent review committee. That combination usually creates a lower evidentiary bar than randomized PFS or OS studies, and a clear response signal can support a “positive” outcome if it beats weak historical salvage-therapy activity. Offsetting that, this remains a tough, previously treated metastatic setting, and the entry criterion is HER2-expressing rather than a narrower HER2-amplified/high-overexpression group, which could dilute efficacy if benefit is concentrated in stronger expressers. No prior efficacy signal is provided in the trial fields, so asset-level proof of concept is uncertain. The study also still shows as recruiting despite the estimated primary completion date having passed, adding operational and disclosure risk. Overall, this looks modestly favorable, but not convincingly so.

SHR-A1811 is a third-generation HER2-directed ADC from Jiangsu HengRui with strong prior data directly relevant to this trial. At ASCO 2025, a separate phase 2 study (NCT05896020) reported SHR-A1811 in 35 cervical cancer patients achieving an ORR of 63.6%, with PFS of 10.7 months and no treatment discontinuations or deaths. The drug has demonstrated consistent efficacy across multiple HER2-expressing tumor types (breast, NSCLC, salivary gland, gastric), with ORRs ranging from 38-86% depending on HER2 expression level and tumor type. This trial uses the same drug, dose, indication, and ORR primary endpoint assessed by IRC. As a single-arm study, the bar for 'positive' is a clinically meaningful ORR versus historical controls, which prior data strongly supports. Key risks include: the trial is past its estimated primary completion but still recruiting, suggesting enrollment delays; IRC assessment may differ from investigator assessment; and patient selection differences could modestly alter outcomes. The strong concordance of prior cervical cancer data tilts probability meaningfully positive.

This is a Phase II single-arm trial of SHR-A1811 (HER2-targeting ADC) in HER2-expressing recurrent/metastatic cervical cancer patients who failed prior systemic therapy. Key considerations: (1) Single-arm design limits interpretability without historical controls; (2) Heavily pretreated population with prior therapy failure typically has poor outcomes; (3) HER2-positive selection is a positive biomarker stratification; (4) ORR by IRC is a validated surrogate endpoint commonly used in Phase II oncology trials; (5) ADC platform has demonstrated efficacy in other HER2-expressing cancers; (6) Jiangsu HengRui is a major Chinese pharma with ADC capabilities. The combination of single-arm design in a difficult-to-treat population suggests modest probability of strongly positive results, though the biomarker-selected HER2 population and ADC mechanism provide some rationale for optimism. Estimate: 45% intrinsic YES probability.

This is a single-arm Phase II trial in a heavily pre-treated, difficult-to-treat population (HER2-expressing recurrent/metastatic cervical cancer). The primary endpoint is ORR, a surrogate, but the lack of a control arm and the advanced disease state make a robust 'positive' result challenging to define and achieve. The sponsor, HengRui, is credible, and the ADC mechanism (SHR-A1811) has precedent, but prior data in this specific niche is limited. The trial is still recruiting, and the primary completion date has passed, suggesting data readout is imminent, which adds disclosure and execution risk. Overall, the intrinsic odds of a clearly positive outcome appear modest.

Single-arm Phase II trial of SHR-A1811 (HER2-targeted, likely ADC) in HER2-expressing recurrent/metastatic cervical cancer post-systemic therapy failure. Patient population challenging: cervical cancer has low HER2 overexpression rates (~5-10%), heterogeneous expression, heavily pretreated with dismal prognosis (mOS ~6-12mo). Trial design appropriate for early signal: multicenter, IRC-assessed ORR up to 2 years, high endpoint quality minimizing bias. No prior SHR-A1811 data in this indication raises uncertainty; success hinges on activity in low/HER2-low expressors. Sponsor Jiangsu HengRui competent in oncology, but primary completion overdue 60 days despite 'recruiting' status flags enrollment/execution risks in rare cohort. Disclosure risk moderate—Chinese firms emphasize positives but adhere to regs. 'Positive' likely ORR exceeding ~15-20% futility bar. Benchmarks: similar refractory targeted trials yield 10-25% ORR without strong enrichment. Plausible modest activity, but biology mismatch caps odds at 42%.

This Phase 2 single-arm trial evaluates SHR-A1811, a HER2-directed ADC, in a refractory cervical cancer population with high unmet need. The primary endpoint is Objective Response Rate (ORR), a standard efficacy marker for accelerated approval. The study is past its estimated primary completion date, suggesting data maturity. HengRui's prior SHR-A1811 data in breast and gastric cancers has shown robust efficacy and a differentiated safety profile, supporting class effects in HER2-expressing tumors. Given the lack of standard therapies for HER2-expressing recurrent cervical cancer, the bar for 'positive' results is clinically attainable. The single-arm design reduces execution risk compared to randomized studies. High probability of success is driven by established ADC mechanism, favorable competitor landscape, and suitable endpoint selection.

SHR-A1811 is an HER2-directed ADC with demonstrated activity in HER2-expressing solid tumors. Phase I/II data in breast cancer showed promising ORR. This single-arm Phase II in HER2-expressing cervical cancer uses IRC-assessed ORR, a rigorous endpoint. The trial completed primary completion 60 days ago but remains recruiting, suggesting data maturity may still be pending. HER2 expression prevalence in cervical cancer is modest (~5-20%), limiting target population but enriching for responsive patients. Prior systemic therapy failure indicates a refractory population, potentially dampening response rates. Single-arm design lacks comparator but is standard for accelerated approval pathways. Chinese sponsor with limited Western regulatory track record introduces execution and disclosure uncertainty. Overall, modestly positive outlook based on mechanism and precedent, tempered by indication-specific data scarcity and geographic disclosure risks.

This is a single-arm Phase 2 trial evaluating the ORR of SHR-A1811 (a HER2-directed ADC) in patients with HER2-expressing recurrent or metastatic cervical cancer. The intrinsic probability of a positive outcome is extremely high due to robust, directly applicable prior data. At ASCO 2025, results from a similar Phase 2 study (NCT05896020) demonstrated that SHR-A1811 elicited an outstanding ORR of 63.6% and a progression-free survival of 10.7 months in a cohort of 35 cervical cancer patients. This establishes clear proof-of-concept and heavily derisks the primary efficacy endpoint for this dedicated trial. The historical benchmark for standard-of-care therapies in heavily pretreated cervical cancer is generally around 15-25% ORR, making a >60% response rate a clear clinical success. Hengrui has extensive experience executing such oncology trials in China, minimizing operational risks. While some typical topoisomerase I ADC toxicities (like interstitial lung disease) exist, the safety profile has previously been characterized as manageable. Given the overwhelmingly positive precursor data and low benchmark for standard-of-care, the trial is highly likely to meet its primary endpoint and be declared positive.

The trial is a Phase II study of SHR-A1811 in HER2-expressing recurrent/metastatic cervical cancer. The primary endpoint is Objective Response Rate (ORR) assessed by Independent Review Committee (IRC). Given that the drug targets a specific HER2-expressing population and has shown potential in previous studies, there's a reasonable expectation of positive results. However, being a single-arm trial with a relatively small sample size and the aggressive nature of the cancer, there are risks. The sponsor, Jiangsu HengRui Medicine Co., Ltd., has a track record of developing effective treatments. Overall, these factors contribute to a moderately high probability of a positive outcome.